狼疮新药研发又有新进展，治疗策略转向“长期缓解与器官保护”

Core Insights - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that imposes a significant burden on patients, families, and society, necessitating a focus on controlling disease activity while minimizing long-term treatment risks [1][2] Group 1: Disease Characteristics - SLE is characterized by an immune system that mistakenly attacks the body's own tissues and organs, leading to diverse clinical manifestations [2] - Approximately 45% of SLE patients in China experience kidney involvement, and 37% have blood system abnormalities, with these rates being higher than in Western populations [2] - China has the highest number of SLE patients globally, predominantly affecting young women of childbearing age, with an average onset age of around 30 years [2] Group 2: Treatment Landscape - Historically, SLE treatment options were limited, primarily relying on steroids and immunosuppressants, leading to a "drug scarcity" situation for patients [3] - Long-term use of steroids can result in significant side effects, including obesity, osteoporosis, and elevated blood sugar levels, while immunosuppressants may increase infection risks [3] - The treatment strategy for SLE is shifting from "symptom control" to "long-term remission and organ protection," with the concept of "targeted therapy" emerging to maintain low disease activity or clinical remission [3] Group 3: Advances in Treatment - Recent advancements in treatment options, including biological agents, small molecule drugs, and cell therapies, have revolutionized SLE management [3] - Effective management of steroid use is crucial, as maintaining steroid levels without reduction equates to not achieving treatment goals [3] - The evolving treatment landscape aims to balance the reduction of steroid-related side effects with the risk of disease relapse during tapering [3]